Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ).
Ab&B Bio-Tech CO., LTD. JS has announced the commencement of Phase I clinical trials for its adjuvanted quadrivalent and trivalent subunit influenza vaccines. These vaccines, targeting individuals aged 65 and above, aim to provide enhanced immune responses through an MF59-like adjuvant, addressing the severe impact of influenza on the elderly. This development marks a significant step in the company’s strategic focus on premium vaccines, potentially strengthening its market position in China and internationally.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods. The company aims to replace traditional and imported vaccines in China and expand its presence in international markets, with a product range that includes the quadrivalent subunit influenza vaccine and lyophilized human rabies vaccine candidate.
Average Trading Volume: 361,716
Learn more about 2627 stock on TipRanks’ Stock Analysis page.